,i #aahth ,,congress #b;d ,session ,h4 ,r4 #fifc ,,in ,,the ,,house ,,of ,,representatives ,january #aa1 #bjbd,ms4 ,eshoo 7for herself1 ,ms4 ,de,gette1 and ,ms4 ,schrier7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to direct the ,secretary of ,health and ,human ,services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,pediatric ,cancer ,drug ,supply ,act of #bjbd4 #b4 ,establishment of essential pediatric cancer drug marketplace stability pilot program 7a7 ,in general ,the ,secretary shall carry out a pilot program under which the ,secretary enters into agreements with manufacturers to purchase and maintain not less than a #f-month reserve supply1 to be held by such manufacturers1 of each covered pediatric cancer drug4 7b7 ,pilot program 7#a7 ,preference for multiple manufacturers ,to the greatest extent practicable1 the ,secretary shall seek to enter into agreements described in subsection 7a7 with more than #a manufacturer for each covered pediatric cancer drug4 7#b7 ,implementation goals ,to the greatest extent practicable1 the ,secretary shall implement the pilot program under this section in a manner that-- 7,a7 minimizes the impact on the marketplace for drugs included on the essential pediatric cancer drug list established under section #c2 7,b7 increases domestic manufacturing capacity2 7,c7 encourages competition in the marketplace2 7,d7 assures that any covered pediatric cancer drugs that the ,secretary distributes or orders to be distributed under section #d are used to treat pediatric cancer patients2 and 7,e7 rewards manufacturing quality4 7#c7 ,required agreement terms ,each agreement under this section between the ,secretary and a manufacturer of a covered pediatric cancer drug shall include the following3 7,a7 ,the identity and quantity of each covered pediatric cancer drug that the manufacturer agrees to hold in reserve supply4 7,b7 ,a requirement that such quantities shall be in addition to the average levels of inventory for the relevant covered pediatric cancer drug held by the manufacturer during the previous year4 7,c7 ,a provision to ensure that each drug held in reserve supply has an expiration date at least #a year beyond the current date4 7,d7 ,a provision to allow the manufacturer to sell and replace1 through normal commercial channels1 any drug in reserve supply in order to remain in compliance with the provision described in subparagraph 7,c74 7,e7 ,a requirement that the covered pediatric cancer drugs in reserve supply may only be held at a location in the ,united ,states4 7,f7 ,in the case of a covered pediatric cancer drug manufactured at an eligible source facility that is not located in the ,united ,states1 the manufacturer of such drug may comply with subparagraph 7,e7-- 7i7 by storing the drug at an establishment located in the ,united ,states that is-- 7,i7 registered under section #eaj of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj72 and 7,,ii7 under common ownership and control with the manufacturer2 or 7ii7 by contracting with an authorized third-party logistics provider 7as defined in section #eha of the ,federal ,food ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;eee77 located in the ,united ,states to store the drug in the ,united ,states4 7,g7 ,a requirement that any covered pediatric cancer drug held in reserve supply be manufactured and held in accordance with-- 7i7 good manufacturing practice requirements2 7ii7 the approved application for such drug under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 or section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb72 and 7iii7 applicable law4 7,h7 ,a provision that allows the ,secretary1 or a third party designated by the ,secretary1 to audit the manufacturer and the eligible source facility for compliance with the terms of the agreement and applicable law-- 7i7 on an annual basis2 or 7ii7 more frequently1 if the ,secretary has a reasonable basis to believe that the manufacturer or eligible source facility is not complying with the terms of the agreement or applicable law4 7,i7 ,a requirement that the manufacturer certify to the ,secretary on an annual basis compliance with the terms of the agreement4 7#d7 ,optional terms for acquisition1 construction1 alteration1 or renovation of establishment ,an agreement under this section between the ,secretary and a manufacturer of a covered pediatric cancer drug may include a provision to allow the manufacturer to acquire1 construct1 alter1 or renovate a non-federally owned establishment for the purpose of manufacturing covered pediatric cancer drugs-- 7,a7 as the ,secretary determines necessary to ensure sufficient amounts of such drugs2 or 7,b7 as the ,secretary determines necessary to carry out or improve preparedness and response capability at the ,state and local levels4 7#e7 ,reasonable time for manufacture ,the ,secretary shall allow each manufacturer with whom the ,secretary has entered into an agreement under this section a reasonable amount of time after entering into the agreement to manufacture the covered pediatric cancer drugs that will be held in reserve supply pursuant to the agreement4 7c7 ,payment terms 7#a7 ,payment amounts 7,a7 ,in general ,the amount paid to each manufacturer pursuant to an agreement with the ,secretary under this section shall be based on-- 7i7 the quantity of each covered pediatric cancer drug the manufacturer agrees to hold in reserve supply2 and 7ii7 the wholesale acquisition cost of each such drug4 7,b7 ,administrative fee ,the ,secretary may pay a manufacturer an administrative fee pursuant to an agreement under this section1 provided that the payment of the administrative fee does not cause the ,secretary to exhaust the amounts appropriated for the pilot program under this section prior to securing adequate reserves for each covered pediatric cancer drug4 7#b7 ,payment conditioned on reserve supply adequacy 7,a7 ,in general ,except as provided in subparagraph 7,b71 each agreement with a manufacturer under this section shall provide that no payment under the agreement may be made until the manufacturer demonstrates to the ,secretary that the manufacturer has set aside a portion1 as determined by the ,secretary1 of the total quantity of the covered pediatric cancer drug to be held in reserve supply under the agreement4 7,b7 ,exceptions for advance payment ,an agreement under this section may provide that1 if the ,secretary determines that an advance payment or partial payment for significant milestones is necessary to ensure success of the terms of the agreement1 the ,secretary shall pay1 in advance1 an amount not to exceed #aj percent of the total amount to be paid to the manufacturer by the ,secretary under the agreement4 7d7 ,forfeiture ,if a manufacturer is unable or fails to distribute a covered pediatric cancer drug in accordance with the terms of an agreement entered into under this section1 the manufacturer shall-- 7#a7 forfeit any payments it has received under the agreement2 and 7#b7 not later than #cj days after the date of such inability or failure1 refund such payments4 #c4 ,essential pediatric cancer drug list 7a7 ,in general ,the ,secretary1 in consultation with the ,commissioner of ,food and ,drugs and the ,director of the ,national ,cancer ,institute1 shall-- 7#a7 not later than #aej days after the date of enactment of this ,act1 develop a list of chemotherapeutic drugs that are essential for treating pediatric cancer2 and 7#b7 update such list on a schedule determined by the ,secretary4 7b7 ,criteria ,under subsection 7a71 a chemotherapeutic drug shall be considered essential for treating pediatric cancer only if the drug-- 7#a7 is approved under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 or licensed under section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7 for use in the treatment of cancer2 7#b7 has the potential alone or in combination with other drugs to treat a pediatric cancer2 7#c7 is supported by #a or more citations to treat a pediatric cancer included or approved for inclusion in-- 7,a7 the ,national ,comprehensive ,cancer ,network ,compendia2 7,b7 ,american ,hospital ,formulary ,service ,drug ,information2 7,c7 the ,,drugdex ,information ,system2 or 7,d7 the ,,pdq ,cancer ,information ,summaries for ,health ,professionals of the ,national ,cancer ,institute2 and 7#d7 meets price1 quality1 manufacturing concentration1 manufacturing complexity1 and other appropriate metrics as determined by the ,secretary4 #d4 ,distributions from essential pediatric cancer drug reserve supplies 7a7 ,in general ,if a covered pediatric cancer drug is in shortage 7as defined in section #ejf;,c7h7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef;c7h7771 or the ,secretary has reason to believe that such a drug may be at risk of such a shortage1 the ,secretary may order a manufacturer with whom the ,secretary has entered into an agreement under section #b to distribute such drug from the reserve supply in accordance with such agreement in an effort to alleviate or prevent the shortage4 7b7 ,payments for distribution 7#a7 ,in general ,the ,secretary shall require a recipient of a covered pediatric cancer drug distributed under subsection 7a7 to pay the ,secretary for such drug4 ,the amount of such payment shall not exceed the price for which the ,secretary purchased such drug pursuant to an agreement under section #b4 7#b7 ,limitation ,the ,secretary may use payments received pursuant to paragraph 7#a7 only to replenish the reserve supply of the drugs distributed under subsection 7a74 7c7 ,inability ,to distribute or manage reserve supply 7#a7 ,inability to distribute ,if a manufacturer is not able or willing to distribute drugs in accordance with an order of the ,secretary under subsection 7a71 the ,secretary may take possession of and distribute such drugs4 7#b7 ,inability to manage reserve supply ,if a manufacturer can no longer hold or manage a reserve supply of covered pediatric cancer drugs in accordance with an agreement under section #b1 the ,secretary may take possession of the reserve supply4 #e4 ,reports to ,congress 7a7 ,in general ,for each year #a or more drugs are held by a manufacturer in reserve supply pursuant to an agreement under section #b1 the ,secretary shall submit to ,congress a report on the progress of the pilot program under such section4 7b7 ,contents ,the reports referred to in subsection 7a7 shall each include-- 7#a7 the essential pediatric cancer drug list in effect during the year covered by the report 7including any changes made to the list throughout the year72 7#b7 the total number of agreements entered into under section #b during such year2 7#c7 the total amount of each covered pediatric cancer drug purchased by the ,secretary pursuant to such agreements during such year2 7#d7 the total amount of each covered pediatric cancer drug distributed from the reserve supplies under section #d during such year2 and 7#e7 any other information that the ,secretary determines relevant4 #f4 ,definitions ,in this ,act3 7#a7 ,covered pediatric cancer drug ,the term covered pediatric cancer drug means a drug-- 7,a7 that is included on the essential pediatric cancer drug list established under section #c2 7,b7 that may be at risk of a meaningful disruption 7as defined in section #ejf;,j7j7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef;j7j777 in the supply of the drug2 and 7,c7 whose final dosage form is manufactured at an eligible source facility4 7#b7 ,drug ,the term drug-- 7,a7 means a drug 7as defined in section #bja7;g7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7;g7772 and 7,b7 includes a biological product 7as defined in section #cea7;i7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;i7774 7#c7 ,eligible source facility ,the term eligible source facility means a facility-- 7,a7 registered under section #eaj of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj72 7,b7 lawfully manufacturing a covered pediatric cancer drug2 and 7,c7 located in-- 7i7 the ,united ,states2 or 7ii7 a country that is a member of the ,organisation for ,economic ,co-operation and ,development4 7#d7 ,essential pediatric cancer drug list ,the term essential pediatric cancer drug list means the list under section #c7;a74 7#e7 ,secretary ,the term ,secretary means the ,secretary of ,health and ,human ,services4 7#f7 ,united ,states ,the term ,united ,states means each of the several ,states and the territories and possessions of the ,united ,states4 #g4 ,authorization of appropriations ,to carry out this ,act1 there are authorized to be appropriated #ejj1jjj1jjj for fiscal year #bjbd1 to remain available until expended4